Teleflex (NYSE:TFX) said yesterday it launched its 2nd-generation Percuvance percutaneous surgical system designed for percutaneous laparoscopic procedures in the U.S.
The company said that along with the launch, the 1st clinical use of the device, in a sleeve gastrectomy, Roux-en-Y gastric bypass, and laparoscopic gastric band removal, were recently performed at the Duke Center for Metabolic and Weight Loss Surgery.
“These are increasingly common but often challenging procedures. Our experiences with the new system are consistent with other clinical studies, which showed that its handling and functionality were similar to standard 5-mm laparoscopic instrumentation. Further research will determine whether the system’s smaller incisions could potentially demonstrate improvements in patient pain, cosmesis, and satisfaction,” Dr. Dana Portenier of Duke Regional Hospital, who performed the 1st procedure with the device, said in a press release.
The newly released system features interchangeable 5mm tool tips and a quick-connect system for changing tool-tips while the system is outside the body. The company said the device is usable in advanced general laparoscopic procedures, including laparoscopic cholecystectomy, upper gastrointestinal, gastric, bariatric, colorectal and hernia procedures.
“Our 2nd-generation Percuvance system represents a significant advancement in the ongoing and perpetual evolution of minimally invasive surgery and is demonstrative of Teleflex’s unwavering commitment to innovation. We are encouraged by surgeons’ enthusiastic response to our percutaneous surgical devices and are optimistic the new Percuvance system will become a new standard of care in laparoscopic surgery,” prez & GM John Tushar said in a prepared statement.
The company’s 1st version was released in March last year, and the 2nd generation version has received clearance from the FDA and CE Mark approval in the European Union.
In May, Teleflex said it closed a $400 million debt offering round through the offering of 4.875% senior notes due in 2026.
The Wayne, Penn.-based company said it expects to net approximately $393 million from the offering after deducting underwriters discounts and commissions, and intends to use the proceeds to repay borrowings from its revolving credit facility, according to an SEC filing.
